Viral Photodisruption and Immune Modulation: The Photochemical and Hormetic Basis of Ultraviolet Blood Irradiation

Influenza represents a persistent and dynamic global health challenge, characterized by annual epidemics and the ever-present specter of a high-mortality pandemic, particularly from avian-origin strains like H5N1. Current therapeutic arsenals, predominantly reliant on viral neuraminidase inhibitors and RNA polymerase inhibitors, face significant limitations including narrow windows of efficacy, the rising prevalence of antiviral resistance, and an inability to modulate the deleterious host immune responses that often dictate clinical severity. Ultraviolet Blood Irradiation (UBI) emerges as a compelling, mechanistically distinct therapeutic platform that warrants urgent re-evaluation. By leveraging the photonic disruption of viral genomes and simultaneous immunomodulation, UBI operates on principles governed by photochemical kinetics and hormetic dose-response relationships. This intervention employs ultraviolet light to directly inactivate circulating viral particles through nucleic acid photodamage while simultaneously reprogramming the host immune system—a "dual-strike" strategy that simultaneously reduces viral load and mitigates immunopathology. This stands in stark contrast to conventional antivirals, which solely target viral replication and can inadvertently spare the immunopathological cascade responsible for acute respiratory distress syndrome (ARDS) and fatal outcomes, especially in H5N1 infections. However, the authors emphasize that no direct experimental data on UBI against H5N1 currently exist in the peer-reviewed literature; this absence is a critical gap that the proposed research agenda seeks to address. The mechanistic foundation of UBI is rooted in well-established photochemical and photobiological principles, allowing for a quantitatively predictable and tunable therapeutic dose. This review synthesizes historical evidence, recent preclinical data, and the established safety profile of analogous extracorporeal phototherapy to build a case for UBI as a viable adjunctive treatment for severe influenza. While in vitro and animal model studies, including promising data against influenza, provide a compelling rationale, a critical gap exists in high-quality clinical research specific to influenza viruses, and the available animal data are preliminary, unreplicated, and derived from a single unpublished study. This work argues that the convergence of pandemic preparedness needs, the limitations of current antivirals, and UBI's unique mechanism positions it not as an alternative but as a necessary complementary strategy. We propose a focused research agenda beginning with in vitro dose-response studies against H5N1, progressing to optimized animal challenge models with independent replication , and culminating in human clinical trials, to definitively establish UBI's role in pandemic and severe seasonal influenza management.